Search Within

Shanu Modi

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (21)
  2. Meeting Abstract (19)
  3. Review (1)
Groups
  1. Breast Medicine Service (41)
  2. Department of Medicine (41)
  3. GSK Faculty (41)
  4. Molecular Pharmacology and Chemistry Program Faculty (41)
  5. Sloan Kettering Institute Faculty (41)
  6. Solid Tumor Oncology Division (41)

More Groups

People
  1. Clifford Hudis (21)
  2. Gabriela Chiosis (18)
  3. Neal Rosen (16)
  4. Adriana Dionigi Corben (12)
  5. Tony Taldone (12)
  6. Komal Jhaveri (11)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (6)
  6. 2018 (1)

More Years

Publications
  1. Cancer Research (8)
  2. Journal of Clinical Oncology (7)
  3. Clinical Cancer Research (4)
  4. Breast Cancer Research and Treatment (2)
  5. Clinical Breast Cancer (2)
  6. Nature Communications (2)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (8)
  3. Nature Publishing Group (4)
  4. Cell Press (2)
  5. Elsevier Inc. (2)
  6. Springer (2)

More Publishers

Results (41)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ex vivo treatment response of primary tumors and/or associated metastases for preclinical and clinical development of therapeutics
    Journal Article

    Corben, A. D.; Uddin, M. M.; Crawford, B.; Farooq, M.; Modi, S.; Gerecitano, J.; Chiosis, G.; Alpaugh, M. L.
    Journal of Visualized Experiments (2014)

    Fulltext@MSK | Save
  • Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions
    Journal Article

    Jhaveri, K.; Ochiana, S. O.; Dunphy, M. P. S.; Gerecitano, J. F.; Corben, A. D.; Peter, R. I.; Janjigian, Y. Y.; Gomes DaGama, E. M.; Koren, J. 3rd; Modi, S.; more...
    Expert Opinion on Investigational Drugs (2014)

    Fulltext@MSK | Save
  • Using (124)I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Gajria, D.; Taldone, T.; Alpaugh, M.; DaGama, E. G.; Uddin, M.; Chiosis, G.; Lewis, J. S.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A comprehensive study to analyze tumor sensitivity to HSP90 inhibition therapy
    Meeting Abstract

    Riolo, M.; Modi, S.; Corben, A.; Hudis, C.; Alpaugh, M.; Chiosis, G.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Journal Article

    Beylergil, V.; Morris, P. G.; Smith-Jones, P. M.; Modi, S.; Solit, D.; Hudis, C. A.; Lu, Y.; O'Donoghue, J.; Lyashchenko, S. K.; Carrasquillo, J. A.; more...
    Nuclear Medicine Communications (2013)

    Fulltext@MSK | Save
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i)
    Meeting Abstract

    Jhaveri, K. L.; Iyengar, N. M.; Corben, A.; Patil, S.; Akram, M.; Towers, R.; Sakr, R.; Hudis, C.; King, T. A.; Rosen, N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
    Journal Article

    Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G.
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save